Findings

What do systematic reviews say?

9 questions · 10 findings · 2 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 30%GRADE not reported 1 · 10%Very low 0 · 0%Low 2 · 20%Moderate 4 · 40%High 0 · 0%

Methotrexate vs placebo

Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP

Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).

1 finding from 1 review

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory… 2017 · Cochrane Headline outcomes only
RR 1.21 [0.4, 3.7]
1 study · 59 participants
Moderate

Methotrexate vs placebo

Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP

1 finding from 1 review

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Low

Methotrexate vs placebo

Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP

1 finding from 1 review

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Low

Methotrexate vs placebo

Serious adverse events · people with CIDP

Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory… 2017 · Cochrane Headline outcomes only
RR 3.56 [0.39, 32.23]
1 study · 59 participants
Moderate

Methotrexate vs placebo

Muscle strength · people with inclusion body myositis

2 findings from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
GRADE not reported
Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Moderate

Methotrexate vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate vs placebo

Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate vs placebo

Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate vs placebo

Significant adverse events · people with inclusion body myositis

Methotrexate probably leads to higher significant adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
RR 8.76 [1.19, 64.28]
1 study · 44 participants
Moderate